Press Release

Asia Pacific Cell and Gene Therapy Biomanufacturing Market to Grow with a CAGR of 16.25% through 2028

Surge in research and development activities is expected to drive the Asia Pacific Cell and Gene Therapy Biomanufacturing Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Asia Pacific Cell and Gene Therapy Biomanufacturing Market – By Country, Competition, Forecast and Opportunities, 2018-2028F”, the Asia Pacific Cell and Gene Therapy Biomanufacturing Market stood at USD1.73 billion in 2022 and is anticipated to grow with a CAGR of 16.25% in the forecast period, 2023-2028. The initiatives taken by government based on cell and gene therapy biomanufacturing has led to favorable market conditions for the Asia Pacific Cell and Gene Therapy Biomanufacturing Market. Several factors contribute to the growth of various cell and gene therapy biomanufacturing market products.

AusBiotech, the leading biotechnology industry association in Australia, has recently unveiled a comprehensive blueprint aimed at establishing a seamless and integrated value chain encompassing the entire lifecycle of cell and gene therapies. This groundbreaking initiative encompasses the key stages of discovery, development, manufacture, and distribution, and is set to revolutionize the field by accelerating the translation of cutting-edge research into real-world therapies that can transform patients' lives.

With its strong emphasis on policy and advocacy work, AusBiotech is actively engaged in productive discussions with the Australian Federal Government to drive support and foster an enabling environment for the advancement of cell and gene therapies. This collaborative approach is crucial in realizing the full potential of these innovative treatments and ensuring their accessibility to patients in need.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Asia Pacific Cell and Gene Therapy Biomanufacturing Market


The recent surge in research and development (R&D) activities can be attributed directly to the pressing global health challenges and the growing demand for advanced therapeutics. In particular, the ongoing COVID-19 pandemic has highlighted the critical need to expedite the development of innovative therapies and vaccines. This sense of urgency has not only intensified R&D efforts but has also significantly bolstered activities in the field of cell and gene therapy biomanufacturing. With the aim of addressing the unmet medical needs and combating various diseases, this increased focus on R&D is paving the way for groundbreaking advancements in the field, offering hope for improved healthcare outcomes and a brighter future.

The Asia Pacific Cell and Gene Therapy Biomanufacturing Market is segmented into equipment, application, regional distribution, and company.

Based on its equipment, the bioreactors/fermenters segment held the largest share in the market. The revenues generated by sales of bioreactors and fermenters used for manufacturing antibodies contribute significantly to the current market. Antibodies, as a crucial component of many cell and gene therapies (CGTs), underscore the essential role of bioreactors and fermenters in the production of these life-changing therapies. With the increasing demand for CGTs, the need for efficient and scalable bioreactor and fermenter technologies becomes even more pronounced. These advanced systems provide a controlled environment for the growth and cultivation of cells, ensuring high-quality and consistent production of antibodies for therapeutic applications.

As the field of biomanufacturing continues to evolve, the continuous improvement and innovation in bioreactor and fermenter technologies are anticipated to drive further advancements in CGTs, opening new possibilities for the treatment of various diseases.

Based on country, China segment is expected to grow during the forecast period.

In recent years, China, along with several other countries in the Asia Pacific region, has been grappling with a significant rise in the prevalence of chronic diseases. The burden of these conditions has prompted a surge in the exploration and application of innovative treatment approaches. Among the most promising are cell and gene therapies, which hold immense potential in addressing these complex health challenges. As a result, there has been an escalating demand for these advanced therapies, spurring the expansion of the cell and gene therapy biomanufacturing market within the country. This trend reflects a concerted effort to meet the growing healthcare needs of the population and advance the field of personalized medicine, making China a key player in the global landscape of regenerative medicine.

Major companies operating in Asia Pacific Cell and Gene Therapy Biomanufacturing Market are:

  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Danaher Corporation
  • Endress+Hauser Group Services AG (Analytik Jena GmbH)
  • General Electric Company
  • Getinge AB
  • Infors AG
  • Lonza Group Ltd
  • Merck KGaA


Download Free Sample Report

Customers can also request for 10% free customization on this report


“Growing application of cell and gene therapy biomanufacturing in various end user industries are key drivers of the cell and gene therapy biomanufacturing market. Growth in competitive landscape and presence of well-established companies in the market who are dedicated to enhance their productivity of cell and gene therapy biomanufacturing with every passing year are anticipated to register an impressive growth to Asia Pacific Cell and Gene Therapy Biomanufacturing Market in the forecast period.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Asia Pacific Cell and Gene Therapy Biomanufacturing Market By Equipment (Bioreactors/Fermenters, Mixing Systems, Cell Counters, Cell Sorters, Centrifuges, Incubators, Biosafety Cabinets, Freezers, PCR Systems, Transfection Systems, Storage Tanks, Others), By Application (Formulation and Hydration, Cell Culture Processing, Separation and Filtration, Others), By Country, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Asia Pacific Cell and Gene Therapy Biomanufacturing Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Asia Pacific Cell and Gene Therapy Biomanufacturing Market.


Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News